This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-Learn About Coagulation Disorders
-What are Bleeding Disorders?
 History of Bleeding Disorders
 Types of Bleeding Disorders
 Types of Bleeds
 Bleeding Disorders and Women
 Caring for the Newly Diagnosed Child
 Psychosocial Issues
-Complications, including Inhibitors
-For Consumers
 What is an Inhibitor?
 Who is at Risk for Developing an Inhibitor?
 How Do You Know If You Have an Inhibitor?
 Test Results
 Porcine Factor VIII
-Immune Tolerance
 Treatment Costs and Financial Considerations
 For Providers
 Discussion Group
 Future Therapies
 What are Clotting Disorders?
 Comprehensive Medical Care - Hemophilia Treatment Centers
 Medical and Scientific Advisory Council
 Financial and Insurance Issues
 HANDI, NHF's Information Resource Center
 Web Links



Immune Tolerance

While the treatments discussed in the preceeding sections provide options for treating a bleed, they do not have the same positive, long-term outcomes as treatment with replacement factor (VIII or IX) in patients without inhibtiors. These less-than-optimal treatments can also lead to secondary problems such as infections, bleeding into joints and organ damage.

Because of these complications, many healthcare providers believe that ridding of the body of inhibitors is the best option. This is done using a course of therapy known as "immune tolerance." There are different treatment programs used for immune tolerance, but most require repeated exposure to the deficient clotting factor.

People who opt for immune tolerance expose themselves to daily doses of factor over a period of weeks, and in some cases, years. Some people going through this therapy are also given immune suppressive drugs, which can predispose one to infections. The risks and benefits of each treatment program and the medications used should be discussed in detail with a healthcare provider. The goal of immune tolerance therapy is to eventually "teach" the body to tolerate the factor and to not mount an immune response so that normal replacement therapy can be used to prevent or control bleeding.

Overall, immune tolerance treatment is highly effective and is thought to work approximately 60% to 80% of the time.



This section of our Web site is sponsored by: